title: Temsirolimus in patients with renal cancer on hemodialysis.
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Lunardi
authors.forename: Maria Ornella
authors.initials: MO
authors.lastname: Vannozzi
authors.forename: Andrea
authors.initials: A
authors.lastname: Armirotti
authors.forename: Maurizio
authors.initials: M
authors.lastname: Nicodemo
authors.forename: Marco
authors.initials: M
authors.lastname: Venturini
authors.forename: Lucia
authors.initials: L
authors.lastname: Cavallini
mesh_terms: D000284:Administration, Oral; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D019540:Area Under Curve; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy; D009362:Neoplasm Metastasis; D006435:Renal Dialysis; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; C401859:temsirolimus; D020123:Sirolimus